Darunavir inhibitory quotient predicts the 48-week virological response to darunavir-based salvage therapy in human immunodeficiency virus-infected protease inhibitor-experienced patients.

Darunavir inhibitory quotient predicts the 48-week virological response to darunavir-based salvage therapy in human immunodeficiency virus-infected protease inhibitor-experienced patients.

Data de publicació online: 01/01/2008

Abstract:

IF: 4,390, Q: 1st. Pharmacology

Autors: Molto, J., Santos, J. R., Perez-Alvarez, N., Cedeno, S., Miranda, C., Khoo, S., Else, L., Llibre, J. M., Valle, M., and Clotet, B.
  • Codi Doi: Antimicrob Agents Chemother 52, 3928-3932.

Subscriu-te a la newsletter

Back to Top
Irsi Caixa

Impulsat per:

'La Caixa' Generalitat de Catalunya - Departament de Salut

 

HR Excellence in Research

Membre de:

Cerca

Amb la col·laboració de: